Trial results for nipocalimab in adults with generalized myasthenia gravis (gMG) were posted on ClinicalTrials.gov on 2025-07-23. The Phase 3 study (NCT04951622) demonstrated that nipocalimab led to a greater improvement in Myasthenia Gravis - Activities of Daily Living (MG-ADL) total score compared to placebo, with a difference in least squares means of -1.45 (p=0.002).
Background
Generalized myasthenia gravis (gMG) is a chronic autoimmune neuromuscular disease characterized by fluctuating weakness of voluntary muscles. The study investigated nipocalimab as a potential treatment for adults living with this condition.
Trial design
The study, titled "A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis" (NCT04951622), is a Phase 3 trial. It has an enrollment of 199 participants diagnosed with Myasthenia Gravis. The interventions included nipocalimab, placebo, and a subcutaneous formulation of nipocalimab sc-liv. The study's purpose was to evaluate the efficacy and safety of nipocalimab compared to placebo. A subcutaneous substudy aimed to evaluate pharmacodynamics when administered as an injection under the skin compared to intravenously.
Key results
The trial evaluated the "Double-blind (DB) Phase: Average Change From Baseline in Myasthenia Gravis - Activities of Daily Living (MG-ADL) Total Score Over Weeks 22, 23, and 24."
- In the Double Blind (DB) Phase: Placebo group, the least squares mean change from baseline was -3.25 (Standard Error: 0.335).
- In the DB Phase: Nipocalimab group, the least squares mean change from baseline was -4.70 (Standard Error: 0.329).
A mixed effects model for repeated measure analysis showed a difference of least squares means of -1.45 (95.0% CI: -2.38 to -0.52) between the groups, with a p-value of 0.002.
What this means
The results indicate that nipocalimab significantly improved MG-ADL scores in adults with generalized myasthenia gravis compared to placebo. The observed reduction in MG-ADL total score suggests a clinically meaningful benefit for patients. These findings support the potential of nipocalimab as a treatment option for gMG.
Source
The information regarding these trial results was obtained from ClinicalTrials.gov, a public database of clinical studies. The results for study NCT04951622, titled "A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis," were posted on 2025-07-23 on clinicaltrials.gov.